A 55-year-old man with acute myeloid leukemia in second relapse presented 4 months after haploidentical CD34 þ -selected hematopoietic stem cell transplantation (HSCT) with symmetric, progressive neurological deficits of the lower extremities. Although there was no molecular evidence for drug resistance in the cerebral-spinal fluid, antiviral combination therapy failed to control the rapidly progressing CMV polyradiculopathy (PRP) and encephalitis, which were confirmed by autopsy studies. Late CMV PRP as an unusual manifestation of CMV disease should be kept in mind in patients with suggestive neurological symptoms after HSCT.
stem cell transplantation; cytomegalovirus; polyradiculopathy Pre-emptive antiviral therapy has reduced early cytomegalovirus (CMV) disease after allogeneic hematopoietic stem cell transplantation (HSCT), but the development of late disease with a poor prognosis is increasingly reported. [1] [2] [3] Late disease seems to be associated with atypical manifestations such as retinitis, ventriculoencephalitis and polyradiculopathy (PRP), previously considered characteristic for AIDS patients.
2-4 CMV PRP has been described in advanced HIV infection, but not after HSCT. 4 We describe a patient who developed CMV PRP after undergoing haploidentical HSCT.
Case report
A 55-year-old male patient with AML (FAB M1) diagnosed 17 months previously received haploidentical peripheral blood stem cell transplantation (PBSCT) from his son in second relapse. (Fresenius, Graefeling, Germany) 20 mg/kg per day was administered from days À5 to À1, as described for haploidentical HSCT. 5 Both the donor and recipient were CMV seropositive (D þ /R þ ). CMV antigenemia was monitored weekly by pp65 antigen detection, as described previously. 6 Pre-emptive ganciclovir (5 mg/kg twice daily i.v.) therapy was started on positive antigenemia result and was switched to foscarnet (60 mg/kg twice daily i.v.) in case of clinical evidence for drug resistance. The post transplantation course was complicated by recurrent episodes of CMV reactivation and a constantly low CD4 count, as depicted in Figure 1 . On day þ 137, the patient presented with paresthesia in both feet. Neurological examination revealed bilaterally absent Achilles tendon reflexes, lower limb weakness, as well as loss of soft touch and temperature sensation in a symmetric distribution on both lower extremities. CMV polymerase-chain reaction (PCR) of the cerebral-spinal fluid (CSF) was repeatedly positive and magnetic resonance imaging (MRI) of the spine and head showed unspecific alterations ( Figure 2a ). CMV disease was suspected and induction treatment with foscarnet, as well as two cycles of intravenous immunoglobulin infusions, was administered (30 g daily for 5 days). With CMV antigen dropping to 0 on day þ 147, deep tendon reflexes being progressively releasable and improving paresthesia, the patient was discharged. Unfortunately, on day þ 193, the patient was readmitted with acute confusional state, progressive tetraparesis and urinary retention. CMV-PCR of the CSF was positive, MRI of the head demonstrated progressive localized white matter changes (Figure 2b ). Since the patient's condition worsened despite antiviral combination treatment, two separately gathered CSF specimens were screened twice for CMV genotype mutations. Sequences between nucleotides 1234 and 1961 of the UL97 coding region that confer ganciclovir resistance were amplified by PCR, as previously described, and were negative. patient died on day þ 215. The characteristic findings for CMV PRP and encephalitis were histologically and immunohistochemically confirmed by autopsy studies (Figure 2c and d) .
Discussion
CMV disease of the CNS is diagnosed most frequently in advanced HIV infection, but is much less frequent in patients immunosuppressed due to other causes such as solid organ or HSCT. 8 Delayed immune reconstitution with consistently low CD4 counts, combined with immunosuppression in HSCT recipients, allows for a high rate of virus replication, as reflected in our patient by the recurrent antigenemia (Figure 1 ). This high replication rate in combination with pre-emptive antiviral therapy may lead to resistance through drug pressure, and continuous antiviral therapy delays the recovery of CMV-specific T-cell immunity.
3,9,10 Both mechanisms might contribute to the development of atypical late CMV manifestations. Since continued antigenemia and T-lymphopenia were identified as strong predictors of late CMV disease, our patient met the high-risk criteria. 10 On initial presentation, our patient demonstrated four of the five characteristic criteria of CMV PRP in AIDS patients. The symptoms hyporeflexia and lower limb weakness were described in 100% of all cases, paresthesia and sensory loss in 80%. 4 When being readmitted, he disclosed even the fifth criteria, urinary retention (94% of all previously described cases). 4 The mortality of CMV PRP in AIDS patients is 100% and the mean survival time after diagnosis is 13 weeks, which corresponds to the poor course of our patient. 4 Since Guillain-Barre´syndrome was a possibility, our patient received intravenous immunoglobulin in addition to antiviral therapy. The initial clinical improvement suggested that this therapeutic approach was effective. Flowcytometric analysis during the period of repeatedly high viremia revealed a severe T-lymphopenia as detailed in Figure 1 . Conversely, when clinical manifestation of PRP became overt, the CD4 count was increasing and viremia responded to therapy. Although molecular ganciclovir resistance was not detected, the clinical course of our patient is suggestive for the presence of a resistant virus strain in the CNS. However, the chance for DNA polymerase mutation in the absence of UL97 mutation is low; there is still a possibility of DNA polymerase resistance mutations, not examined in this study.
Other reasons for the nonresponsiveness to antiviral treatment in our patient might have been the low CNS penetration of the most effective antiviral drugs, in combination with impaired local immune surveillance. Ganciclovir has poor CNS penetrance with CNS levels reported at 24-67% of that of plasma and the brain penetration is reported at 38% of that of plasma. 11 Thus, with improved survival after HSCT, T-lymphocyte depleted or CD34 þ selected grafts, intensified immunosuppressive regimens and longer antiviral drug exposure, late disease in association with atypical manifestations could become a growing clinical challenge in the post HSCT setting and might require long-term secondary prophylaxis such as high-dose valacyclovir or valgancilovir treatment, or adoptive immunotherapy with CMV-specific T cells.
We conclude that late CMV PRP as an atypical manifestation of CMV disease, following prolonged preemptive treatment, should be kept in mind when searching for pathogens causative for neurological symptoms in patients post HSCT.
